Home    Back

46. Malignant rheumatoid arthritis
4,183 clinical trials,   2,538 drugs   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-UMIN000042632
2020/01/0103/12/2020THE EFFECT OF LASER THERAPY ON EARLY ONSET RHEUMATOID ARTHRITIS PATIENTSTHE EFFECT OF LASER THERAPY ON EARLY ONSET RHEUMATOID ARTHRITIS PATIENTS - laser effectiveness in rheumatoid arthritis Rheumatoid arthritislow level laser therapy. Each patient in group 1 takes 20 sessions of LLLT , in the form of 2 courses, each course contains 10 sessions ,as 3 sessions every week ,10 days free between 2 courses.
The laser apparatuses used for therapy in this study were the following,
1.HeNe Laser wavelength 632,8 nm, continuous emission, output power 7.3 mW.
2.GaAIAs diode laser (830 nm, maximum output power 300 mW).
12 patients
placebo laser and naproxen
Naproxen is given as tablet 500mg twice per day.
12 patients
naproxen
Naproxen is given as tablet 500mg twice per day.
10 patients		Rheumatology clinic at Al-Kindy Teaching Hospital /Baghdad/IraqNULLComplete: follow-up complete20years-old80years-oldMale and Female34Not applicableAsia(except Japan)
2NCT03312465
(ClinicalTrials.gov)		September 28, 201712/10/2017Anatomical Shoulder Domelock System StudyAnatomical Shoulder™ Domelock System A Multicenter, Prospective, Non-Controlled Post-Market Clinical Follow-up StudyAdvanced Wear and Tear of the Shoulder Joint;Avascular Necrosis;Conditions Consequent to Earlier Operations;Omarthrosis;Rheumatoid Arthritis;Revision of Shoulder ProsthesisDevice: AS Domelock SystemZimmer BiometNULLRecruiting18 Years80 YearsAll123Belgium;Germany;Switzerland;United Kingdom
3NCT03719469
(ClinicalTrials.gov)		January 20, 20156/9/2018Circulating microRNAs as Novel Prognosis Biomarkers for Rheumatoid ArthritisCirculating microRNAs Expression as Predictors of Clinical Response in Rheumatoid Arthritis Patients Treated With Green TeaRh DiseaseDietary Supplement: Green tea groupKing Saud UniversityNULLCompleted18 Years85 YearsAll150NULL
4NCT02257047
(ClinicalTrials.gov)		October 20142/10/2014Red Yeast Rice and Subclinical Atherosclerosis in Patients With Rheumatoid ArthritisRheumatoid ArthritisDietary Supplement: Tea;Dietary Supplement: RYRChengdu PLA General HospitalNULLEnrolling by invitation18 Years75 YearsAll120N/AChina
5ChiCTR-TRC-12003871
2009-05-012012-01-01Phase II of Tong Luo Hua Shi Capsules in Rheumatoid ArthritisA Multi-center, Randomized, Double-blind, Phase II Study Evaluating the Safety and Efficacy of Tong Luo Hua Shi Capsules in Participants with Rheumatoid Arthritis Rheumatoid arthritisA:2 pieces of Tong Luo Hua Shi Capsules. Votalin and Leflunomide Tablets when necessary;B:3 pieces of Tong Luo Hua Shi Capsules. Votalin and Leflunomide Tablets when necessary;C:4 pieces of Tong Luo Hua Shi Capsules. Votalin and Leflunomide Tablets when necessary;D:4 pieces placebo;The First Teaching Hospital of Tianjin University of Traditional Chinese MedicineNULLCompleted1868BothA:60;B:60;C:60;D:60;I+2 (Phase 1;Phase 2)China
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6JPRN-UMIN000001798
2008/07/0125/03/2009Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study) Rheumatoid arthritisInjection of etanercept by 50 mg/week for one year
Injection of etanercept by 25 mg/week for one year		Team RA, Rheumatosurgery, Osaka City University Medical SchoolNULLComplete: follow-up complete20years-old80years-oldMale and Female100Not applicableJapan
7ChiCTR-TRC-11001755
2007-10-012011-12-01Phase II of Tu Fu Ling Tablets in Rheumatoid ArthritisA Multi-center, Randomized, Double-blind, Double-dummy, Phase II Study Evaluating the Safety and Efficacy of Tu Fu Ling Tablets in Participants with Rheumatoid Arthritis Rheumatoid ArthritisA:Tu Fu Ling Tablets, 200mg Bid. Other: Placebo;B:Tu Fu Ling Tablets, 100mg Tid. Other: Placebo. ;C:Leflunomide Tablets, 20mg Qd. Other: Placebo;The First Teaching Hospital of Tianjin University of Traditional Chinese MedicineNULLCompleted1865BothA:80;B:80;C:80;2 (Phase 2 study)China
8EUCTR2004-002006-30-GB
(EUCTR)		17/11/200417/02/2005Triple therapy in early active rheumatoid arthritis - TEARTriple therapy in early active rheumatoid arthritis - TEAR Rheumatoid arthritisProduct Name: Methotrexate
INN or Proposed INN: Methotrexate
Trade Name: Salazopyrin En-Tabs
Product Name: sulfasalazine
INN or Proposed INN: Sulfasalazine
Trade Name: Plaquenil
Product Name: Hydroxychloroquine
INN or Proposed INN: Hydroxychloroquine		North Glasgow NHS TrustNULLNot RecruitingFemale: yes
Male: yes		96United Kingdom
9NCT00259610
(ClinicalTrials.gov)		May 200428/11/2005Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)Rheumatoid ArthritisDrug: methotrexate;Drug: sulfasalazine;Drug: hydroxychloroquine;Drug: etanerceptUniversity of Alabama at BirminghamAmgen;Barr Laboratories;PfizerCompleted18 YearsN/AAll755Phase 4United States

Back to top